Note: This list contains duplicate records, as identified by the OpenAIRE deduplication algorithm based on metadata analysis.

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial The Lancet · 2019 · 10.1016/s0140-6736(19)30650-6
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial The Lancet · 2019 · 10.17863/cam.37618
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial The Lancet · 2019 · 31178152
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial The Lancet · 2019 · PMC6615016